Federated Hermes
GMAB icon

Federated Hermes’s Genmab GMAB Stock Holding History

Federated Hermes’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.6M Buy
1,251,590
+572,211
+84% +$17.1M 0.05% 351
2025
Q4 		$20.9M Buy
679,379
+256,441
+61% +$7.99M 0.04% 450
2025
Q3 		$13M Buy
+422,938
New +$10.3M 0.02% 508
2023
Q4 		– Sell
-4,686
Closed -$165K – 2098
2023
Q3 		$165K Buy
4,686
+8
+0.2% +$305 ﹤0.01% 1549
2023
Q2 		$178K Sell
4,678
-34,360
-88% -$1.37M ﹤0.01% 1563
2023
Q1 		$1.47M Sell
39,038
-645,540
-94% -$24.8M ﹤0.01% 1054
2022
Q4 		$29M Buy
684,578
+119,990
+21% +$4.94M 0.08% 296
2022
Q3 		$18.1M Sell
564,588
-13,145
-2% -$462K 0.05% 404
2022
Q2 		$18.8M Sell
577,733
-85,682
-13% -$2.78M 0.05% 400
2022
Q1 		$24M Sell
663,415
-26,524
-4% -$910K 0.05% 396
2021
Q4 		$27.3M Buy
689,939
+878
+0.1% +$36.6K 0.05% 414
2021
Q3 		$30.1M Sell
689,061
-6,561
-0.9% -$295K 0.06% 388
2021
Q2 		$28.4M Sell
695,622
-218,948
-24% -$8.45M 0.05% 401
2021
Q1 		$30M Sell
914,570
-112,008
-11% -$4.21M 0.06% 389
2020
Q4 		$41.7M Sell
1,026,578
-171
-0% -$6.39K 0.09% 292
2020
Q3 		$37.6M Buy
1,026,749
+1,287
+0.1% +$46.5K 0.09% 262
2020
Q2 		$34.8M Sell
1,025,462
-38,285
-4% -$1.04M 0.09% 272
2020
Q1 		$22.5M Sell
1,063,747
-71,694
-6% -$1.6M 0.07% 317
2019
Q4 		$25.4M Buy
1,135,441
+154,900
+16% +$3.38M 0.06% 353
2019
Q3 		$19.9M Buy
+980,541
New +$19.3M 0.05% 372

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Federated Hermes's GMAB Position: Q1 2026 in Review

Federated Hermes increased its Genmab (GMAB) stake by 84% in Q1 2026, buying an estimated $17.1M and bringing the position to 1,251,590 shares worth $33.6M. The position accounts for 0.05% of the portfolio, ranked #351.

Federated Hermes first reported a position in GMAB in Q3 2019 and has held it in 20 quarters since. The position peaked at $41.7M in Q4 2020. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Federated Hermes held 1,251,590 shares of Genmab worth $33.6M as of Q1 2026.
  • Federated Hermes bought 572,211 Genmab shares in Q1 2026, an estimated $17.1M.
  • Genmab made up 0.05% of Federated Hermes's portfolio in Q1 2026, its #351 holding.
  • Federated Hermes first reported a position in Genmab in Q3 2019 and has held it in 20 quarters since.
  • Federated Hermes's Genmab position peaked at $41.7M in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.